The cognitive and nootropic peptide category is smaller than some others on the platform but the compounds in it work through genuinely different mechanisms and have different research bases behind them. This thread is an overview of what compounds are in this category, how they relate to each other, and what researchers in this space are studying.
The category is more diverse than it appears.
Unlike the GLP-1 category (where everything is a receptor agonist for one receptor family) or the GH peptide category (where everything is a secretagogue), the cognitive peptide category covers genuinely different mechanisms. ACTH-derived modulators (Semax), peptide neuromodulators (Selank), neurotrophic peptide complexes (Cerebrolysin), and angiotensin IV analogs (Dihexa) all sit in this category but work through different pathways and have very different research bases supporting them. The Mechanism thread covers each mechanism in more depth.
The major compounds researchers are studying.
Semax. A heptapeptide derived from a fragment of ACTH (adrenocorticotropic hormone) without the ACTH-related endocrine effects. Originally developed in Russia and used clinically there for stroke recovery and cognitive endpoints. The published research base includes Russian-language studies and a smaller body of English-language preclinical work. Mechanism involves BDNF (brain-derived neurotrophic factor) upregulation and modulation of monoamine neurotransmission. Typically administered intranasally because the peptide does not survive oral digestion well and intranasal delivery achieves reasonable brain penetration.
Selank. A synthetic peptide based on a fragment of human tuftsin. Developed in parallel to Semax in Russian research programs. Studied for anxiolytic effects, stress modulation, and some cognitive endpoints. The mechanism appears to involve modulation of GABAergic and serotonergic systems without the dependence or withdrawal profile of conventional benzodiazepines. Typically intranasal administration.
Cerebrolysin. A complex porcine-brain-derived peptide preparation containing a mixture of low-molecular-weight peptides and amino acids. Has been used clinically in many countries for decades for stroke recovery, traumatic brain injury, dementia, and other neurological indications. The research base is substantial and includes randomized clinical trials, though the mixed-peptide preparation makes mechanism characterization more complex than for single-molecule compounds. Typically administered as injection (intramuscular or intravenous in clinical settings).
Dihexa. A small peptide derived from angiotensin IV that crosses the blood-brain barrier and has been studied for hippocampal effects. Marketed in the research community based on early preclinical findings — but the published research base is much thinner than for the other compounds in this category, the long-term safety profile is not well characterized, and the marketing claims often outrun the data. The Red Flags thread in this category covers the marketing problem in detail.
Other compounds in this space. The category also includes compounds like P21 (ciliary neurotrophic factor analog), various BPC-157 cognitive applications (covered separately in the BPC-157 category), and peptide fragments being investigated for specific cognitive endpoints. The research base on most of these is very early.
The blood-brain-barrier question.
A central practical issue across this category is whether a given peptide actually crosses the blood-brain barrier in concentrations that produce CNS effects. Most peptides do not cross the BBB efficiently, which is why intranasal administration dominates this category — intranasal delivery bypasses the BBB through the cribriform plate route, achieving brain penetration that systemic administration would not. The Mechanism thread covers BBB considerations for each compound.
Routes of administration vary across the category.
Semax and Selank are essentially intranasal-only for cognitive applications. Some research uses injection but the intranasal route is overwhelmingly dominant in both clinical and research use.
Cerebrolysin is essentially injection-only — the peptide complex is too large and structurally heterogeneous for intranasal delivery, and the clinical use pattern is intramuscular or intravenous depending on the protocol.
Dihexa has been studied with multiple routes including oral (the small molecule is more orally accessible than larger peptides) and injection. The oral bioavailability claims for Dihexa have not been thoroughly verified and should be approached with appropriate skepticism.
What is being researched.
For Semax: cognitive enhancement endpoints in healthy subjects, stroke recovery applications, ADHD-related research, neuroprotection in various contexts, and BDNF-mediated effects.
For Selank: anxiolytic effects without dependence profile, stress modulation, immune modulation effects (related to its tuftsin origin), and some cognitive endpoints.
For Cerebrolysin: stroke recovery (the largest clinical research base), dementia and Alzheimer's research, traumatic brain injury recovery, and various neurological indications.
For Dihexa: cognitive endpoints in preclinical models, hippocampal effects, and proposed effects on various neurological conditions where the supporting research base is thin.
What the VialTalk research community tends to focus on.
Comparative experiences with Semax versus Selank for different research applications. The intranasal versus injectable route question. The BBB penetration question across compounds. Dosing protocols and timing for nootropic effects research. Vendor quality, particularly for Cerebrolysin (where the porcine-brain origin creates specific quality verification challenges) and Dihexa (where the published research base is much thinner than the marketing implies).
Where to go next.
The deeper threads in this category cover specific topics. The Selank-versus-Semax comparison thread covers head-to-head considerations. The Dihexa thread covers the controversies around the compound. The Mechanism + Half-Life thread in this Research Library covers the pharmacology in depth. The Quality + COA thread covers vendor evaluation specific to this category, including the Cerebrolysin-source and Dihexa-research-base concerns. The Red Flags thread covers the specific scam patterns including the Dihexa marketing problem and the Cerebrolysin counterfeit issue.
